Katharina M. Duchardt

Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

S. Tenzer, H. Schild, S. Held, 2009, Cancer Immunology, Immunotherapy.

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

M. Fotin‐Mleczek, J. Probst, C. Lorenz, 2011, Journal of immunotherapy.

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

A. Thess, M. Fotin‐Mleczek, C. Lorenz, 2012, The journal of gene medicine.

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

A. Thess, M. Fotin‐Mleczek, C. Lorenz, 2012, The journal of gene medicine.